A 20 year old patient has been on the typical antipsychotic Chlorpromazine (Thorazine). He is experiencing a flat affect, withdrawal from interpersonal relationships, and poor hygiene. What medication change would the NP suggest?

Chlorpromazine (Thorazine) is a first-generation antipsychotic used in schizophrenia, primarily effective for positive symptoms such as hallucinations and delusions. However, typical antipsychotics can worsen or fail to improve negative symptoms like flat affect, social withdrawal, and poor self-care. Negative symptoms are more closely linked to dopamine dysfunction in the mesocortical pathway and respond better to medications with broader dopamine-serotonin activity. Treatment adjustment is often needed when negative symptoms predominate or worsen. Rationale: A. Switching to lithium such as Lithium (Lithobid) is not appropriate because lithium is used for bipolar disorder and mood stabilization, not for primary treatment of schizophrenia negative symptoms. It does not address psychotic symptoms or negative symptom clusters such as avolition or flat affect. B. Switching to another typical antipsychotic like Haloperidol (Haldol) would likely not improve negative symptoms and may further exacerbate them due to strong dopamine D2 blockade. Typical antipsychotics are more effective for positive symptoms and are associated with extrapyramidal side effects, which can worsen functional impairment and social withdrawal. C. Switching to an atypical antipsychotic such as Risperidone (Risperdal) is appropriate because atypical agents target both dopamine and serotonin receptors, providing better coverage for both positive and negative symptoms. These medications are more effective in improving affect, motivation, and social functioning compared to typical antipsychotics. They also have a lower risk of extrapyramidal side effects at standard doses. D. Increasing the dose of Chlorpromazine (Thorazine) is not appropriate because it may worsen side effects without improving negative symptoms. Higher doses increase the risk of sedation, anticholinergic effects, and extrapyramidal symptoms, all of which can further impair functioning and quality of life. Negative symptoms are not dose-responsive to typical antipsychotic escalation.